We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Tag: monoclonal antibodies
MedXY News
EnglishTag

monoclonal antibodies

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Sibeprenlimab Achieves 51% Reduction in Proteinuria for IgA Nephropathy: Key Interim Insights from the Phase 3 VISIONARY Trial
Internal MedicineIgA nephropathymonoclonal antibodies

Sibeprenlimab Achieves 51% Reduction in Proteinuria for IgA Nephropathy: Key Interim Insights from the Phase 3 VISIONARY Trial

By MedXY|Feb 22, 2026

The Phase 3 VISIONARY trial interim analysis demonstrates that sibeprenlimab, a monoclonal antibody targeting APRIL, significantly reduces proteinuria and pathogenic IgA1 in patients with IgA nephropathy, offering a promising upstream thera

Significant 1-Year Risk of Cardiovascular Events in Cognitive Impairment Highlights Safety Concerns for Anti-Amyloid Therapy
CardiologyAlzheimer's diseaseanticoagulation
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story

Significant 1-Year Risk of Cardiovascular Events in Cognitive Impairment Highlights Safety Concerns for Anti-Amyloid Therapy

By MedXY|Jan 6, 2026

A longitudinal study reveals that over 5% of patients with MCI or dementia develop new indications for anticoagulants or thrombolytics within a year, complicating the use of anti-amyloid monoclonal antibodies due to increased intracranial h

Coramitug Significantly Reduces NT-proBNP in Transthyretin Amyloid Cardiomyopathy: Phase 2 Trial Results
CardiologyATTR-CMCardiology

Coramitug Significantly Reduces NT-proBNP in Transthyretin Amyloid Cardiomyopathy: Phase 2 Trial Results

By MedXY|Dec 25, 2025

A Phase 2 randomized trial shows that coramitug, a monoclonal antibody targeting misfolded transthyretin, significantly reduced NT-proBNP levels by 48% in patients with ATTR-CM. While functional outcomes remained stable over 52 weeks, the r

Targeted Monoclonal Antibody Therapy: Sotrovimab Shows Mortality Benefit in Hospitalized COVID-19 Patients with High Antigen Loads
Infectious DiseasesCOVID-19monoclonal antibodies

Targeted Monoclonal Antibody Therapy: Sotrovimab Shows Mortality Benefit in Hospitalized COVID-19 Patients with High Antigen Loads

By MedXY|Dec 23, 2025

The RECOVERY trial demonstrates that sotrovimab significantly reduces 28-day mortality in hospitalized COVID-19 patients with high baseline serum antigen levels, highlighting the potential for biomarker-guided monoclonal antibody therapy de

Early Clinical Evaluation of Novel Broadly Neutralising Monoclonal Antibodies for HIV-1: Safety, Pharmacokinetics, and Neutralisation Profiles of N6LS, PGDM1400LS, and PGT121.414.LS
Clinical UpdatesHIVmonoclonal antibodies

Early Clinical Evaluation of Novel Broadly Neutralising Monoclonal Antibodies for HIV-1: Safety, Pharmacokinetics, and Neutralisation Profiles of N6LS, PGDM1400LS, and PGT121.414.LS

By MedXY|Nov 13, 2025

This review summarizes early-phase clinical trials assessing the safety, pharmacokinetics, and neutralisation activity of three innovative broadly neutralising monoclonal antibodies—N6LS, PGDM1400LS, and PGT121.414.LS—for HIV-1 prevention a

Targeting Claudin-1: A Novel Therapeutic Approach for Primary Sclerosing Cholangitis
Gastroenterologyliver fibrosismonoclonal antibodies

Targeting Claudin-1: A Novel Therapeutic Approach for Primary Sclerosing Cholangitis

By MedXY|Oct 28, 2025

Claudin-1 is upregulated in primary sclerosing cholangitis (PSC), promoting biliary fibrosis and cholestasis. Preclinical models show that Claudin-1-specific monoclonal antibodies reduce liver injury and fibrosis, highlighting a promising t

Alzheimer’s Disease: Navigating Controversies and Shaping Future Strategies
NeurologyAlzheimer's diseasebiomarkers

Alzheimer’s Disease: Navigating Controversies and Shaping Future Strategies

By MedXY|Oct 10, 2025

Recent advances in anti-β amyloid monoclonal antibodies offer promising reductions in Alzheimer’s disease progression but spark debate regarding their clinical impact, cost-effectiveness, and accessibility. Emerging biomarkers and preventiv

Emerging APRIL-Targeted Therapies in IgA Nephropathy and IgA Vasculitis Nephritis: Clinical Advances with Zigakibart, Sibeprenlimab, and Telitacicept
Allergy & ImmunologyIgA nephropathymonoclonal antibodies

Emerging APRIL-Targeted Therapies in IgA Nephropathy and IgA Vasculitis Nephritis: Clinical Advances with Zigakibart, Sibeprenlimab, and Telitacicept

By MedXY|Oct 4, 2025

Recent clinical trials of APRIL-targeted monoclonal antibodies—zigakibart, sibeprenlimab, and telitacicept—demonstrate safety and significant proteinuria reduction in IgA nephropathy and IgA vasculitis nephritis, offering promising disease-

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities